EMICIZUMAB DATA
Quality of Life
The Genentech resources below are patient-friendly summaries of data related to emicizumab and quality of life topics. These patient-friendly summaries include studies with the strongest and most relevant data and are provided only for educational purposes. You are encouraged to discuss any questions you have about your condition and any current or potential treatments with your healthcare provider.
Quality of Life Results With HEMLIBRA in Hemophilia A Without Inhibitors
Quality of Life Results With HEMLIBRA in Hemophilia A With Inhibitors
Select publications and scientific data presentations with the strongest and most relevant data are provided below.
Emicizumab Prophylaxis Improves Acute and Chronic Pain-Related Outcomes in People With Haemophilia A (PwHA): Post Hoc Analysis of 470 Patients From HAVEN 1, 3, 4 and STASEY
Hermans C, Skinner MW, Gentile B, et al. Presented at EAHAD; February 7-10, 2023.
The Effect of Emicizumab Prophylaxis on Health-Related Outcomes in Persons With Haemophilia A With Inhibitors: HAVEN 1 Study.
Oldenburg J, Mahlangu JN, Bujan W, et al. Haemophilia. 2019;25:33–44.
Health-Related Quality of Life and Caregiver Burden of Emicizumab in Children With Haemophilia A and Factor VIII Inhibitors - Results From the HAVEN 2 Study
Mancuso ME, Mahlangu J, Sidionio R, et al. Haemophilia. 2020;26(6):1009–1018.
Emicizumab Prophylaxis Improves Long-Term Physical Health Scores in Persons With Haemophilia A (PwHA) With or Without Inhibitors: Update From the HAVEN 3 and HAVEN 4 Studies
Skinner M, Negrier C, Paz-Priel I, et al. Presented at ISTH; July 6-10, 2019.